Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus.

Kerry A CaseyMichael A SmithDominic SinibaldiNickie L SetoMartin P PlayfordXinghao Wang Philip M CarlucciLiangwei WangGabor IlleiBinbing YuShiliang WangAlan T RemaleyNehal N MehtaMariana J KaplanWendy I White

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2021)

These data support a key role for type I IFNs in modulating factors contributing to SLE vasculopathy and suggest that inhibition of this pathway could decrease cardiovascular risk in individuals with SLE.

Keyphrases

systemic lupus erythematosus
disease activity
electronic health record
signaling pathway
dendritic cells
big data
rheumatoid arthritis
machine learning